Drug Profile
BP3m controlled release - Alteogen
Alternative Names: NexP-BP3mLatest Information Update: 28 Apr 2017
Price :
$50
*
At a glance
- Originator Alteogen
- Developer Alteogen; BioCure
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Chronic obstructive pulmonary disease
Most Recent Events
- 28 Apr 2017 Discontinued for Chronic obstructive pulmonary disease in South Korea (unspecified route)
- 23 Dec 2015 Early research in Chronic obstructive pulmonary disease in South Korea (unspecified route)